A formidable problem in developing effective immunotherapy for PDA is the striking immunosuppressive and ‘immune-privileged’ tumor microenvironment. Few patients exhibit robust T cell infiltration in the tumor microenvironment, although when this does occur patient survival is prolonged. Read more . . .
Pancreatic cancer remains a lethal tumor that is difficult to treat and, unfortunately, immune therapies that have garnered FDA approval in other tumors have shown little efficacy to date in this tumor. These therapies include checkpoint antibodies and engineered T cell infusions.